Volume 2024, Issue 1 9925970
Research Article
Open Access

Molecular Insights into the Breast and Prostate Cancer Cells in Response to the Change of Extracellular Zinc

Shital K. Barman

Shital K. Barman

School of Science, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia westernsydney.edu.au

Search for more papers by this author
Monokesh K. Sen

Monokesh K. Sen

Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown 2006, NSW, Australia sydney.edu.au

Search for more papers by this author
David A. Mahns

David A. Mahns

School of Medicine, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia westernsydney.edu.au

Search for more papers by this author
Ming J. Wu

Corresponding Author

Ming J. Wu

School of Science, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia westernsydney.edu.au

Search for more papers by this author
Chandra S. Malladi

Corresponding Author

Chandra S. Malladi

Proteomics and Lipidomics Lab, School of Medicine, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia westernsydney.edu.au

Search for more papers by this author
First published: 12 January 2024
Academic Editor: Yuan Seng Wu

Abstract

Zinc dyshomeostasis is manifested in breast and prostate cancer cells. This study attempted to uncover the molecular details prodded by the change of extracellular zinc by employing a panel of normal and cancerous breast and prostate cell lines coupled with the top-down proteomics with two-dimensional gel electrophoresis followed by liquid chromatography-tandem mass spectrometry. The protein samples were generated from MCF-7 breast cancer cells, MCF10A normal breast cells, PC3 prostate cancer cells, and RWPE-1 normal prostate cells with or without exogenous zinc exposure in a time course (T0 and T120). By comparing the cancer cells vs respective normal epithelial cells without zinc treatment (T0), differentially expressed proteins (23 upregulated and 18 downregulated in MCF-7 cells; 14 upregulated and 30 downregulated in PC3 cells) were identified, which provides insights into the intrinsic differences of breast and prostate cancer cells. The dynamic protein landscapes in the cancer cells prodded by the extracellular zinc treatment reveal the potential roles of the identified zinc-responsive proteins (e.g., triosephosphate isomerase, S100A13, tumour proteins hD53 and hD54, and tumour suppressor prohibitin) in breast and prostate cancers. This study, for the first time, simultaneously investigated the two kinds of cancer cells related to zinc dyshomeostasis, and the findings shed light on the molecular understanding of the breast and prostate cancer cells in response to extracellular zinc variation.

1. Introduction

Zinc (Zn2+) is essential to life. It functions in the cell as a cofactor for well over 300 enzymes and as a structural component for approximately 10% of the human proteome (∼3000 proteins) [1]. Consequently, the cell has developed an elaborate molecular network over the extensive evolutionary timeline to maintain zinc homeostasis. Any disruption of such a network may lead to zinc dyshomeostasis, resulting in health problems such as cancers. Breast cancer is the most common malignancy in females worldwide [2, 3], and prostate cancer in males is the second and fifth highest in incidence and mortality, respectively [2]. Both breast and prostate cancers are associated with intracellular zinc dysregulation. Breast cancer cells exhibit elevated intracellular zinc levels compared to their normal epithelial cells [4], while prostate cancer cells show decreased intracellular zinc levels compared to their normal counterparts [5]. Such diametrically opposite zinc profiles of breast and prostate cancer cells provide an avenue for understanding the role of zinc in these two types of cancer cells.

It is well documented that cellular zinc homeostasis is maintained by Zrt/Irt-like protein (ZIP), Zn2+ transporter (ZnT), and metallothionein (MT) [68]. ZIP family contains 14 members, ZIP1-14 encoded by SLC39A1-14. They increase the cytoplasmic zinc level by importing zinc from the extracellular space or the intracellular organelles/vesicles into the cytoplasm. In contrast, ZnT family, which has 10 members as ZnT1-10 encoded by SLC30A1-10, reduces cytoplasmic zinc by exporting cytoplasmic zinc out of the cell or into the lumens of intracellular organelles. MT family buffers cytoplasmic zinc to maintain zinc homeostasis [9]. The elevated accumulation of intracellular zinc in breast cancer cells or the reduced intracellular zinc in prostate cancer cells is associated with the dynamic expression of ZIP, ZnT, and MT [10, 11]. Previous studies demonstrated that the extracellular zinc exposure resulted in the elevation of intracellular zinc [1215]. Therefore, this study attempts to prod the molecular machinery for zinc homeostasis into action by applying the extracellular zinc exposure and then uncover the dynamic changes by the proteomic approach. As intracellular zinc levels are fluctuating in the cells of living human beings, the dynamic changes in the proteomes of breast and prostate cancer cells are indeed relevant to our understanding of the zinc homeostasis in cancer cells.

Proteomics, complementary to genomics, is an established and essential platform for cancer research [16]. Proteomic analysis on breast and prostate cancer tissues or cell lines or biological fluids from the cancerous individuals was employed in previous studies for the discovery and validation of the predictive, diagnostic, and prognostic markers [1726]. Differential protein profiles have been generated by the proteomics approach employing normal tissues and malignant tissues of low- or high-grade cancers [23]. Comparative proteome analysis reveals changes in the proteins associated with metabolism [20, 27], drug resistance, and metastasis of breast and prostate cancer cells [28, 29]. However, the proteomic profiling has not been simultaneously carried out thus far in normal and cancerous cells of breast and prostate with or without extracellular zinc manipulation. Proteomic insights might be gained by investigating these two types of cancer cells with extracellular zinc manipulation which could prod the cells to action in response to the change of extracellular zinc.

In this study, the top-down proteomic analysis, by two-dimensional gel electrophoresis (2-DE) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS), was systematically carried out on MCF-7 breast cancer cells and MCF10A normal breast epithelial cells, PC3 prostate cancer cells, and RWPE-1 normal prostatic epithelial cells, with and without exogenous zinc exposure. The following comparisons were performed in the data analysis: (1) the cancer cells vs the corresponding normal cells without zinc treatment (T0) including MCF-7 cells vs MCF10A cells and PC3 cells vs RWPE-1 cells, (2) the cancer cells vs the respective normal cells with exogenous zinc treatment for 120 min (T120) including MCF-7 cells T120 vs MCF10A cells T120 and PC3 cells T120 vs RWPE-1 cells T120, (3) comparison of cancer cells between T120 and T0 including MCF-7 cells T120 vs MCF-7 cells T0 and PC3 cells T120 vs PC3 cells T0, and (4) comparison of the normal cells between T120 and T0 including MCF10A cells T120 vs MCF10A cells T0 and RWPE-1 cells T120 vs RWPE-1 cells T0. Such detailed comparative analyses revealed differential protein expression profiles of breast and prostate cells in the context of with or without extracellular zinc treatment, which provides significant insights and enhances our understanding of the breast and prostate cancer cells in response to extracellular zinc variation.

2. Materials and Methods

All the chemicals and reagents were of the highest purity grade from commercial providers as indicated in the methods. All the cell lines were purchased from American Type Culture Collection (ATCC, USA).

2.1. Cell Culture and Protein Extraction from ZnSO4-Treated and Untreated Cells

Breast cells (MCF10A, MCF-7) and prostate cells (RWPE-1, PC3) were cultured in their standard growth media and condition described previously [10]. According to the formulations of the media used here and the available data for the zinc contents in foetal bovine serum [30] and horse serum [31, 32], the base level of zinc for the complete DMEM and RPMI 1640 media is approximately 5 μM, that for the complete DMEM/F12 is approximately 2 μM, and that for the complete keratinocyte serum free medium is 0.5 μM. The mild cytotoxic dosage of ZnSO4 for each cell line was determined by treating the cells with the individual dosages of ZnSO4 including 0, 20, 50, 100, 150, 200, 250, 300, 350, 400, and 500 μM as described in the previous studies [10, 14]. Each dosage was the final concentration of ZnSO4, which was carried out by adding 10 μL of the 20X ZnSO4 stock to the culture well containing 7000 cells in 190 μL medium (the final volume per well was 200 μL). The mild cytotoxic dosage for ZnSO4 was defined as the dosage which resulted in above 70%–85% cell viability at the end of 2 h zinc sulfate treatment. In this study, we used mild cytotoxic ZnSO4 dosages of MCF-7 (320 μM), MCF10A (195.5 μM), PC3 (110 μM), and RWPE-1 (186.88 μM) cells for zinc treatment in proteomic analysis. The rationale for selecting the mild cytotoxic dosages of ZnSO4 is to obtain the datasets on differentially expressed proteins prodded by the dosages without severely compromising the overall health of the cells in the culturing flasks of this study. The viability of cells between 70% and 85% is ideal here, which allows the findings to be relevant to the physiological state of the cells and provides maximum data possible. MCF-7, MCF10A, PC3, and RWPE-1 cells were grown in 75 cm2 flasks until achieving ∼80% confluency and then the spent medium was aspirated and replaced with 11.9 mL of complete medium. ZnSO4 at 120x stock concentration of each dosage for each cell line was prepared in sterile Milli-Q H2O (Milli-Q® Advantage A10 Water Purification System, Merck, Australia). The cells were treated with 100 μL of their respective ZnSO4 stocks. The control cells were treated with 100 μL of sterile Milli-Q water. The cells were incubated for 120 min (T120) and then the protein extraction was performed. Each treatment or control has three biological replicates, which means three protein samples for each time point of a given treatment or control. Each protein sample was prepared with three 75 cm2 flasks of ∼80% confluence.

Following the completion of incubation period, the medium was discarded, and the cells were washed and collected in 1x phosphate-buffered saline (PBS). The cell pellets were obtained by centrifugation at 350 g for 3 min at 4°C and washed with ice cold 1x PBS twice. Finally, the cell pellet was resuspended into 1 mL of ice cold 1x PBS and transferred into sterile 1.5 mL microfuge tubes. The cells were centrifuged at 6000 rpm at 4°C for 5 min and the supernatant was discarded. The cells were snap frozen in liquid nitrogen and stored at −80°C for protein extraction.

150–200 μL of total protein extraction buffer containing 8 M urea (Amresco, Solon, OH, USA), 2 M thiourea (Amresco, Solon, OH, USA), 4% CHAPS (Amresco, Solon, OH, USA), and 1x protease inhibitors (Sigma-Aldrich) was added to each cell pellet in a microfuge tube kept on ice. The cells were then homogenised by using a probe sonicator (Across International, Australia) and centrifuged at 124436 g (SW 55 Ti rotor, Beckman Coulter, Indianapolis, IN, USA) at 4°C for 1 h. The supernatants were collected into individual tubes for either immediate analysis or storage at −80°C.

2.2. Protein Quantification, Reduction, and Alkylation for 2D Gel Electrophoresis

The protein concentration for each sample was estimated using the EZQ™ protein quantitation kit (Life Technologies, Eugene, OR, USA) according to the manufacturer’s instructions. 100 μg of each protein sample was taken in a sterile 0.65 mL microfuge tube. An equal volume of rehydration buffer (containing a mixer of carrier ampholytes (Bio-Lyte, Bio-Rad, Australia) at a final concentration 2% (v/v)) was added to each tube. The sample was then mixed with 2.42 μL of reduction buffer (2 M DTT in 0.2 M TBP) and incubated at 25°C for 1 h on a heating block (Dry Block Heater, Thermoline Scientific, Australia). Following the incubation, 5.1 μL acrylamide (5.6 M) was added to each protein sample for alkylation, vortexed, and incubated at 25°C for further 1 h. The protein samples were then ready for 2D separation.

2.3. First Dimension-Isoelectric Focusing (IEF)

The nonlinear 7 cm long immobilised pH gradient (IPG) strips with pH 3–10 gradients were hydrated with 125 μL of the above-treated protein sample (100 μg). The IEF was then carried out by using Protean IEF apparatus (Bio-Rad, USA) with the following program: desalting at 250 V for 15 min, ramping up the voltage to 4000 V by a linear gradient for 2 h, keeping 4000 V constant for a total of 37500 Vh and then terminating the isoelectric focusing or holding at 500 V until the termination. The temperature of the IEF apparatus during isoelectric focusing was 17°C. Upon completion of the isoelectric focusing, the IPG strips were immediately subjected to the second dimension.

2.4. Second Dimension-Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)

The IPG strips from the first dimension were incubated in 130 mM DTT in equilibration buffer for 10 min followed by 10 min alkylation with 350 mM acrylamide at room temperature on a gentle shaker. Instantly, the IPG strip was placed in warm agarose layer over the stacking gel (5%) which was above the resolving gel (12.5% (w/v) acrylamide, 1 mm thick 8.4 × 7 cm). Once the agarose layer was solidified, the electrophoresis was carried out in 1x tris-glycine-SDS running buffer at 90 V and 4°C for 3 h until the tracking bromophenol blue dye reached the bottom of the gel. Finally, the gels were taken out of the glass plates, promptly dipped into the fixatives (10% methanol with 7% acetic acid) for gel fixation, and then stained with colloidal Coomassie Brilliant Blue (cCBB) for 20 h, followed by destaining with 0.5 M NaCl thrice (15 min each). The gels were imaged by FUJI LAS-4000 (GE Healthcare, USA).

2.5. Protein Spot Detection and Quantitative Analysis

The protein spots were detected and quantitatively analysed in the gel images by Delta2D (version 4.0.8, DECODON Gmbh, Germany) as described previously [33]. The protein spots in the gel images were quantitatively analysed in cancer cells compared to normal cells with or without zinc treatment. Similarly, the protein spots were analysed in each cell line with or without zinc treatment. In each comparison, the gel images were warped and fused to make master gel using “union fusion.” The spots were then transferred to each image in their group to ensure consistent spot matched (100% matching) in all biological replicates (n = 3) in each group. The background-subtracted spot volumes were described as grey values, fold changes, p values (t-test), and relative standard deviation (RSD). Based on p value (p < 0.05) and ratio of grey value, the candidate spots were considered for further proteolytic digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify the proteins.

2.6. Peptide Extraction and LC-MS/MS

The selected protein spots were excised manually and digested with trypsin (Promega, USA) for 8 h at 4°C. The digested protein samples were analysed by LC-MS/MS (Mass Spectrometry Facility, Western Sydney University), using Waters nanoAcquity LC-MS/MSnanoACQUITY UPLC on a Xevo QToF mass spectrometer (Waters, USA) as described previously [34, 35]. The protein identification was conducted employing ProteinLynx Global Server (PLGS) program (version 3.0 Waters Corporation, USA) and the UniProt (Homo sapiens, human) database with the following settings: (a) the allowed maximum missed cleavages was set to 1, (b) the allowed false discovery rate was set to 4% and the maximum protein size was set to 280 kDa, (c) the peptide modifications were carbamidomethyl C (fixed) and oxidation M (variable), (d) the minimum fragment per peptide was 3, (e) the minimum peptide per protein was 1, and (f) the minimum fragment per protein was 7. Finally, the identified proteins from each spot by LC-MS/MS had to meet the selection thresholds such as PLGS or protein score ≥200, sequence coverage ≥6%, and matched peptides ≥3.

2.7. Literature Mining and Bioinformatics

The identified proteins from both breast and prostate cells were searched in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), UniProt (https://www.uniprot.org) database, and PANTHER database (https://www.pantherdb.org) to know their expression status, cellular localisation, molecular function, and protein classes.

2.8. Analysis of Functional Interactions of the Differentially Expressed Proteins

The functional interactions of the differential expressed proteins in breast cells (MCF-7, MCF10A) and prostate cells (PC3, RWPE-1) were analysed using STRING (https://string-db.org/) following the four comparisons, including cancer vs normal cells without zinc exposure (T0), cancer vs normal cells with zinc exposure for 120 min (T120), comparison of cancer cells between T120 and T0, and comparison of the normal cells between T120 and T0.

3. Results

3.1. Differentially Expressed Proteins in Breast Cancer Cells (MCF-7) without Zinc Treatment

By comparing the protein profiles of MCF-7 breast cancer cells against the normal breast epithelial cells (MCF10A), the differentially expressed proteins in breast cancer cells (MCF-7) were identified. Quantitative analysis of the 2-DE gels by DECODON Delta2D software revealed 23 upregulated (red circles) and 18 downregulated (green circles) protein species in MCF-7 breast cancer cells compared to MCF10A normal breast epithelial cells without exogenous zinc exposure (T0) (Figure 1(a)). After LC-MS/MS analysis, the identified proteins are listed in Table 1. The proteins such as 14-3-3 protein σ (SFN), 14-3-3 protein θ (YWHAQ), and protein S100A2 (S100A2) were downregulated in MCF-7 cells, which were shown to have tumour suppression activity by the previous studies [36, 37]. In addition, calcium-binding annexin protein notably annexin A1 (ANXA1) is found to be downregulated. The overexpressed proteins which are associated with breast cancer cell progression and invasion include α-smooth muscle actin α2 (ACTA2), cytochrome b5 type B (CYB5B), D-3-phosphoglycerate dehydrogenase (PHGDH), dihydrolipoamide S-succinyltransferase (DLST), elongation factor Tu (TUFM), F-actin-capping protein subunit β (CAPZB), FUBP1 (FUBP1), glutathione S-transferase Mu 3 (GSTM3), glutathione synthetase (GSS), heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC), high mobility group protein B1 (HMGB1), histone H4 (HIST1H4J), nucleoside diphosphate kinase (NME), proliferating cell nuclear antigen (PCNA), peroxiredoxin 6 (PRDX6), protein S100A13 (S100A13), radixin (RDX), triosephosphate isomerase (TPI1), and tumour protein D53 (TPD52L1).

Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of MCF-7 T0 vs MCF10A T0 and MCF-7 T120 vs MCF10A T120. (a) Representative 2-DE gel images (in the left panel) of breast normal MCF10A cells (MCF10A T0) and breast cancer MCF-7 cells (MCF-7 T0) without zinc exposure (T0). (b) Representative 2-DE gel images (in the right panel) of breast normal MCF10A cells (MCF10A T120) and breast cancer MCF-7 cells (MCF-7 T120) with exogenous zinc exposure for 120 min (T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of MCF-7 T0 vs MCF10A T0 and MCF-7 T120 vs MCF10A T120. (a) Representative 2-DE gel images (in the left panel) of breast normal MCF10A cells (MCF10A T0) and breast cancer MCF-7 cells (MCF-7 T0) without zinc exposure (T0). (b) Representative 2-DE gel images (in the right panel) of breast normal MCF10A cells (MCF10A T120) and breast cancer MCF-7 cells (MCF-7 T120) with exogenous zinc exposure for 120 min (T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Table 1. Identified proteins in breast cancer cells (MCF-7) and normal breast epithelial cells (MCF10A) with or without exogenous zinc exposure.
Spot ID Identified proteins Gene ID Protein accession Theoretical MW (kDa)/pI Observed MW (KDa)/pI PLGS score Matched peptides Sequence coverage (%) (Fold change/p value) Molecular functions
MCF-7 T0/MCF10A T0 MCF-7 T120/MCF10A T120 MCF-7 T120/MCF-7 T0 MCF10A T120/MFC10A T0
1 14-3-3 protein σ SFN P31947 27.8/4.5 27.9/4.5 2586 24 44 (0.5/0.02) ↓ I
2 14-3-3 protein θ YWHAQ P27348 27.8/4.5 29.0/4.7 10806 14 43 (0.4/0.003) ↓ (0.3/0.0001) ↓ II
3 26S proteasome non-ATPase regulatory subunit 4 PSMD4 Q5VWC4 41.1/4.5 62.0/4.6 1085 22 23 (0.2/0.003) ↓ III
4 39S ribosomal protein L12 mitochondrial MRPL12 P52815 21.3/9.2 17.7/5.3 4066 8 30 (0.7/0.03) ↓ IV
5 60S acidic ribosomal protein P0 RPLP0 A0A024RBS2 34.3/5.6 42.0/5.6 588 6 16 (0.3/0.002) ↓ V
6 α-Smooth muscle actin 2 ACTA2 D2JYH4 42.0/5.1 44.4/5.2 6831 22 28 (6.8/0.0003) ↑ (0.3/0.003) ↓ VI
7 Actin cytoplasmic 1 ACTB P60709 41.7/5.1 59.6/5.3 17835 27 60 (0.3/0.0004) ↓ VII
8 Actinin α1 isoform CRA a ACTN1 A0A024R694 103.0/5.1 156.6/5.5 35257 64 45 (1.9/0.02) ↑ VIII
9 Adenosylhomocysteinase AHCY A0A384MTQ3 47.7/5.9 50.1/6.0 911 24 19 (0.5/0.04) ↓ III
10 Annexin ANXA8L1 A0A075B752 40.7/5.6 35.2/5.6 623 8 17 (0.1/0.04) ↓ VIII
11 Annexin A1 ANXA1 P04083 38.7/6.6 36.0/6.6 21563 27 62 (0.2/0.03) ↓ VIII
12 Annexin A5 ANXA5 P08758 35.9/4.7 29.0/5.0 3292 8 20 (0.5/0.03) ↓ (4.4/0.02) ↑ VIII
13 Calmodulin-1 CALM1 P0DP23 17.0/3.9 13.9/3.3 1613 6 41 (0.2/0.006) ↓ VIII, III
14 Cathepsin D CTSD A0A1B0GW44 43.7/6.1 30.2/5.4 1908 11 19 (8.4/0.0001) ↑ (3.3/0.007) ↑ III
15 Cytochrome b5 type B CYB5B O43169 16.3/4.7 18.2/3.7 867 3 17 (4.2/0.0003) ↑ VIII
16 D-3-Phosphoglycerate dehydrogenase PHGDH A0A286YF22 55.9/6.3 69.2/6.7 4302 8 16 (2.0/0.02) ↑ (0.8/0.04) ↓ (1.4/0.02) ↑ III
17 Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) isoform CRA a DLST A0A024R6C9 48.7/9.3 62.0/6.0 1601 4 10 (2.6/0.01) ↑ III
18 Dynactin 2 (P50) isoform CRA c DCTN2 A0A384MDU9 44.2/4.9 59.2/5.2 6320 21 52 (0.4/0.03) ↓ (0.7/0.04) ↓ VII
19 Elongation factor 1 δ EEF1D A0A087X1X7 69.2/6.8 42.0/4.3 52531 21 25 (0.7/0.001) ↓ V
20 Elongation factor Tu TUFM A0A384ME17 49.8/7.4 50.1/7.0 2644 49 36 (5.2/0.01) ↑ (0.5/0.003) ↓ (0.5/0.01) ↓ (1.4/0.02) ↑ V
21 Exosome complex component MTR3 EXOSC6 Q5RKV6 28.2/6.0 32.4/5.9 350 4 17 (0.5/0.04) ↓ IV
22 F-Actin-capping protein subunit β CAPZB A0A384MR50 30.6/5.6 28.5/5.7 1812 10 26 (3.0/0.0003) ↑ (2.4/0.03) ↑ VI
23 ATP-dependent RNA helicase DDX1 DDX1 A0A087X2G1 73.9/7.6 136.2/8.1 298 19 12 (1.4/0.04) ↑ III
24 Adenylosuccinate lyase ADSL A0A1B0GTJ7 54.4/6.7 67.2/7.6 584 4 8 (0.3/0.002) ↓ (0.4/0.005) ↓ III
25 FUBP1 FUBP1 A0A1Z1G4M2 67.6/7.9 89.5/8.2 372 5 9 (2.1/0.02) ↑ II
26 Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4 Q02790 51.8/5.2 62.0/5.6 32827 47 65 (1.9/0.01) ↑ (2.5/0.003) ↑ IX
27 Glutathione S-transferase Mu 3 GSTM3 P21266 26.5/5.2 26.9/5.4 8436 20 54 (3.0/0.04) ↑ (5.0/0.005) ↑ III
28 Glutathione S-transferase P GSTP1 P09211 23.3/5.3 24.6/5.6 12769 31 66 (0.2/0.002) ↓ III
29 Glutathione synthetase GSS P48637 52.4/5.6 62.0/5.6 11269 26 57 (1.5/0.04) ↑ III
30 Inorganic pyrophosphatase PPA1 Q15181 32.6/5.4 37.8/5.5 957 4 11 (2.5/0.03) ↑ III
31 Heat shock protein 90 kDa alpha (cytosolic) class B member 1 isoform CRA a HSP90AB1 A0A024RD80 83.2/4.8 143.0/5.4 5834 28 33 (0.5/0.0006) ↓ IX
32 Heat shock protein β 1 HSPB1 P04792 22.8/6.0 26.0/5.9 46679 22 78 (3.5/0.002) ↑ (0.2/0.002) ↓ IX
33 Pyruvate dehydrogenase E1 component subunit α PDHA1 A0A024RBX9 43.3/8.0 50.1/6.5 373 3 6 (1.7/0.04) ↑ III
34 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC B2R5W2 31.9/4.9 40.8/5.0 7292 24 43 (8.0/0.0002) ↑ (0.5/0.009) ↓ X, IV
35 High mobility group protein B1 HMGB1 A0A024RDR0 24.9/5.5 23.5/6.3 3179 8 26 (1.9/0.03) ↑ X
36 Histidine-tRNA ligase cytoplasmic HARS1 P12081 57.4/5.6 62.0/5.8 3224 15 25 (1.5/0.04) ↑ III
37 Histone H4 HIST1H4J B2R4R0 11.4/11.8 18.2/5.7 897 4 36 (2.5/0.007) ↑ (1.9/0.001) ↑ VII, X
38 Heat shock 70 kDa protein 1A HSPA1A A0A1U9X7W4 70.0/5.3 89.5/5.5 29565 38 49 (1.7/0.02) ↑ IX
39 Inosine-5′-monophosphate dehydrogenase IMPDH A0A384N6C2 55.8/6.5 69.2/7.0 3921 8 14 (0.6/0.04) ↓ (1.5/0.005) ↑ III
40 L-Lactate dehydrogenase B chain LDHB P07195 36.6/5.6 38.9/5.7 6282 11 28 (0.6/0.004) ↓ III
41 C-1-Tetrahydrofolate synthase, cytoplasmic MTHFD1 A0A024R652 101.5/6.8 156.6/7.8 342 18 18 (0.5/0.04) ↓ XI, V
42 Myosin regulatory light chain 12A MYL12A J3QRS3 20.4/4.4 17.3/4.8 1142 5 29 (0.4/0.0003) ↓ VIII
43 NADH dehydrogenase (ubiquinone) iron-sulfur protein 3 mitochondrial NDUFS3 O75489 30.2/7.4 29.0/5.7 1561 5 20 (2.5/0.0004) ↑ III
44 Nucleoside diphosphate kinase NME A0A384MTW7 17.1/5.8 19.1/5.8 3957 6 30 (2.8/0.01) ↑ (1.7/0.03) ↑ III
45 Perilipin PLIN A0A140VJN8 46.9/5.1 55.1/5.1 3760 11 32 (0.1/0.005) ↓ XII
46 Plastin 3 PLS3 P13797 70.8/5.3 92.2/5.6 4429 20 31 (1.8/0.04) ↑ VIII
47 Actin γ ACTG2 P63267 41.9/5.2 47.1/5.1 11163 11 30 (5.2/0.001) ↑ VII
48 Proliferating cell nuclear antigen PCNA P12004 28.8/4.4 36.0/4.7 3412 13 44 (1.5/0.004) ↑ (0.6/0.02) ↓ X
49 Peroxiredoxin 6 PRDX6 A0A024R938 25.0/6.0 26.0/6.3 2521 26 34 (1.9/0.04) ↑ III
50 Proteasome subunit β type 6 PSMB6 P28072 25.3/4.6 21.4/4.9 1361 5 21 (1.4/0.04) ↑ (0.3/0.03) ↓ III
51 Protein S100A2 S100A2 P29034 11.0/4.5 12.0/4.5 2026 3 18 (0.04/0.004) ↓ (0.08/0.01) ↓ (0.4/0.02) ↓ VIII
52 Cytochrome c oxidase subunit 6B1 COX6B1 P14854 10.2/6.9 12.4/5.9 833 8 28 (1.9/0.02) ↑ (0.7/0.04) ↓ XII
53 Protein S100A13 S100A13 Q99584 11.5/5.8 13.1/5.7 9088 17 60 (4.1/0.001) ↑ (4.0/0.0002) ↑ VIII
54 Protein SET SET Q01105 33.5/4.0 50.1/4.4 8811 16 34 (0.2/0.0009) ↓ (0.2/0.0001) ↓ IX, X
55 Radixin RDX B0YJ88 68.5/6.0 110.1/6.3 5828 28 36 (1.3/0.02) ↑ (0.3/0.0004) ↓ (1.6/0.004) ↑ VI
56 Rho GDP-dissociation inhibitor 1 ARHGDIA P52565 23.2/4.8 26.8/5.1 1996 8 28 (0.6/0.04) ↓ III
57 40S ribosomal protein SA RPSA A0A024R2L6 32.8/4.6 47.1/5.1 2510 8 16 (4.4/0.0005) ↑ VII
58 60S acidic ribosomal protein P2 RPLP2 A0A024RCA7 11.7/4.2 15.9/4.3 8497 11 77 (0.7/0.004) ↓ V
59 Serine/threonine-protein kinase PAK 2 PAK2 Q13177 58.0/5.6 73.4/5.8 2239 17 28 (0.5/0.03) ↓ III
60 Serpin B5 SERPINB5 A0A024R2B6 42.1/5.6 45.7/5.8 2466 15 38 (0.2/0.0007) ↓ III
61 START domain-containing 10 isoform CRA a STARD10 A0A024R5L8 33.0/6.7 39.8/6.0 1134 5 20 (3.1/0.002) ↑ XIII
62 Stathmin STMN1 P16949 17.3/5.7 16.5/5.7 8524 12 53 (0.4/0.002) ↓ VII
63 SUMO-1 activating enzyme subunit 1 isoform CRA b SAE1 A0A024R0R4 38.4/5.0 42.0/5.4 3930 11 28 (0.1/0.03) ↓ III
64 T-Complex protein 1 subunit α TCP1 P17987 60.3/5.7 75.5/5.8 4508 17 30 (0.4/0.008) ↓ IX
65 T-Complex protein 1 subunit γ CCT3 B3KX11 57.9/6.5 89.5/6.1 1050 17 23 (0.8/0.02) ↓ IX
66 T-Complex protein 1 subunit θ CCT8 P50990 59.6/5.3 73.4/5.6 1289 15 28 (0.2/0.03) ↓ IX
67 Thioredoxin TXN H9ZYJ2 11.7/4.6 14.5/5.1 1389 15 34 (1.4/0.0004) ↑ III
68 Torsin-1A-interacting protein 1 TOR1AIP1 A0A0A0MSK5 52.4/6.6 75.5/6.1 1086 9 21 (0.2/0.001) ↓ (2.3/0.0005) ↑ III
69 Transitional endoplasmic reticulum ATPase VCP P55072 89.3/5.0 132.3/5.4 2552 27 28 (0.6/0.01) ↓ V, III
70 Triosephosphate isomerase TPI1 P60174 30.8/5.6 25.5/7.7 4224 8 32 (3.0/0.002) ↑ (3.8/0.03) ↑ III
71 Tubulin alpha-1C chain TUBA1C Q9BQE3 50.1/4.8 14.8/5.3 1665 4 12 (0.2/0.0001) ↓ (0.2/00) ↓ (3.1/0.03) ↑ VII
72 Tumour protein D53 TPD52L1 E9PNK6 18.7/5.5 19.1/5.6 1601 3 9 (4.8/0.0005) ↑ (13.6/0.001) ↑ II
73 Tumour protein D54 TPD52L2 A0A087WYR3 23.8/6.1 27.9/5.2 3042 11 38 (2.5/0.04) ↑ II
74 Vesicle amine transport protein 1 VAT1 A0A024R1Z6 41.9/5.9 57.5/6.0 5485 12 21 (0.7/0.04) ↓ III
  • Note. MW stands for molecular weight, kDa for kilo Dalton, pI for isoelectric point, PLGS for ProteinLynx Global Server, T0 for 0 min or without zinc exposure (control), T120 for 120 min, ↑ for upregulation, ↓ for downregulation, MCF-7 for breast cancer cells, and MCF10A for breast normal epithelial cells. The PLGS score, protein accession, theoretical MW/pI, matched peptides, and sequence coverage (%) were obtained using ProteinLynx Global Server (PLGS) software (version 3.0, Waters Corporation, USA) and the UniProt (Homo sapiens, human) database. Gene ID was derived from UniProt database. The observed MW and pI were calculated according to the protein standards. The fold changes and p values were acquired from the quantitative analysis of the gel images (each group n = 3) by Delta2D software (version 4.0.8, DECODON Gmbh, Germany). MCF-7 T0/MCF10A T0 is the expression fold change of the proteins in MCF-7 cells compared to MCF10A cells without zinc exposure (T0), MCF-7 T120/MCF10A T120 is the expression fold change of the proteins in MCF-7 cells compared to MCF10A cells following the zinc exposure for 120 min (T120), MCF-7 T120/MCF-7 T0 is the expression fold change of the proteins in MCF-7 cells following zinc exposure for T120 compared to T0, and MCF10A T120/MFC10A T0 is the fold change of the proteins in MCF10A cells following zinc exposure for T120 compared to T0. Molecular functions: I, apoptosis; II, signalling; III, catalytic activity; IV, RNA binding; V, protein synthesis; VI, protein binding; VII, structural; VIII, metal ion binding; IX, molecular chaperone; X, DNA binding; XI, DNA synthesis; XII, metabolism; XIII, lipid binding.

Based on the molecular functions as per literature survey and UniProt database, those 41 differentially expressed proteins were classified into three prominent groups, including catalytic enzymes (26%), metal ion binding proteins (16%), and molecular chaperones (11%) (Supplementary Figure 1a). PANTHER database-based protein classification agrees with the molecular function-based classification as catalytic enzyme (33%) and calcium binding-protein classes (13%) are the prominent ones (Supplementary Figure 1b). The subcellular localisation classification showed that those proteins are in the cytoplasm (39%), nucleus (22%), and mitochondrion (11%) (Supplementary Figure 1c).

3.2. Differentially Expressed Proteins in MCF-7 Breast Cancer Cells Compared to MCF10A Normal Breast Epithelial Cells following Exogenous Zinc Exposure

The extracellular zinc exposure resulted in 20 downregulated (green circle) and 14 upregulated (red circle) protein spots (Figure 1(b)) in MCF-7 breast cancer cells compared to MCF10A normal breast epithelial cells. Tumour suppressor 14-3-3 protein θ (YWHAQ) and serpin B5 (SERPINB5) were downregulated (Table 1). The suppressed proteins, including D-3-phosphoglycerate dehydrogenase (PHGDH), elongation factor Tu (TUFM), adenylosuccinate lyase (ADSL), inosine-5′-monophosphate dehydrogenase (IMPDH), L-lactate dehydrogenase B chain (LDHB), and perilipin (PLIN), are related to catalytic activity (Table 1). The overexpressed proteins, such as cathepsin D (CTSD), glutathione S-transferase Mu 3 (GSTM3), NADH dehydrogenase (ubiquinone) iron-sulfur protein 3 (NDUFS3), actin γ (ACTG2), protein S100A13 (S100A13), 40S ribosomal protein SA (RPSA), triosephosphate isomerase (TPI1), tumour protein D53 (TPD52L1), and tumour protein D54 (TPD52L2), are associated with cellular structure, cell proliferation, and metastasis (Table 1). The differentially expressed 34 proteins were classified into 38% catalytic, 14% structural, and 8% signalling proteins based on molecular function according to literature survey and UniProt database (Supplementary Figure 2a). PANTHER database-based classification demonstrated three prominent groups including catalytic enzyme (34%), cytoskeletal proteins (11%), and translational proteins (11%) (Supplementary Figure 2b). The proteins showed their subcellular localisation in the cytoplasm (48%), nucleus (18%), and mitochondrion (12%) (Supplementary Figure 2c).

3.3. Differentially Expressed Proteins in MCF-7 Breast Cancer Cells with Exogenous Zinc Exposure Compared to MCF-7 Cells without Zinc Exposure

MCF-7 breast cancer cells demonstrated 16 downregulated (green circle) and 9 upregulated (red circle) protein spots (Figure 2(a)) following exogenous zinc exposure at T120 compared to MCF-7 cells at T0. The downregulated proteins, including α-smooth muscle actin 2 (ACTA2), adenosylhomocysteinase (AHCY), calmodulin 1 (CALM1), heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC), stathmin (STMN1), cytochrome c oxidase subunit 6B1 (COX6B1), and vesicle amine transport protein 1 (VAT1), are related to cancer cell proliferation and migration (Table 1). Tumour suppressor protein S100A2 (S100A2) is downregulated under zinc exposure. The overexpressed proteins, including actinin α1 isoform (ACTN1), annexin A5 (ANXA5), cathepsin D (CTSD), F-actin-capping protein subunit β (CAPZB), inorganic pyrophosphatase (PPA1), and tubulin α1c chain (TUBA1C), are related to cellular structure, growth, or cancer cell invasion (Table 1). Stress protein, heat shock 70 kDa protein 1A (HSPA1A), is overexpressed under zinc exposure. Those 25 proteins (Table 1) were classified into 35% catalytic enzymes, 13% metal binding proteins, and 11% molecular chaperones according to their molecular functions by literature review and UniProt (Supplementary Figure 3a). PANTHER-based classification showed 29% catalytic enzyme and 21% cytoskeletal proteins (Supplementary Figure 3b). The identified proteins are found to be localised in the cytoplasm (48%), nucleus (22%), and cytoskeleton (13%) (Supplementary Figure 3c).

Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of MCF-7 T120 vs MCF-7 T0 and MCF10A T120 vs MCF10A T0. (a) Representative 2-DE gel images (in the left panel) of breast cancer MCF-7 cells without zinc (MCF-7 T0) and with exogenous zinc exposure for 120 min (MCF-7 T120). (b) Representative 2-DE gel images (in the right panel) of breast normal MCF10A cells without zinc (MCF10A T0) and with exogenous zinc exposure for 120 min (MCF10A T120). Each protein extract (100 μg) extract was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of MCF-7 T120 vs MCF-7 T0 and MCF10A T120 vs MCF10A T0. (a) Representative 2-DE gel images (in the left panel) of breast cancer MCF-7 cells without zinc (MCF-7 T0) and with exogenous zinc exposure for 120 min (MCF-7 T120). (b) Representative 2-DE gel images (in the right panel) of breast normal MCF10A cells without zinc (MCF10A T0) and with exogenous zinc exposure for 120 min (MCF10A T120). Each protein extract (100 μg) extract was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.

3.4. Differentially Expressed Proteins in MCF10A Breast Normal Epithelial Cells with Exogenous Zinc Exposure Compared to MCF10A Cells without Zinc Exposure

MCF10A normal breast epithelial cells showed overexpression of 7 protein spots (Figure 2(b)) under exogenous zinc exposure for 120 min (T120) compared to without zinc exposure (T0). D-3-Phosphoglycerate dehydrogenase (PHGDH), elongation factor Tu (TUFM), ATP-dependent RNA helicase DDX1 (DDX1), inosine-5′-monophosphate dehydrogenase (IMPDH), plastin-3 (PLS3), radixin (RDX), and torsin-1A-interacting protein 1 (TOR1AIP1) were related to catalytic activity for cell metabolism and proliferation (Table 1). The classification of these proteins is described in Supplementary Figures 4a–4c.

3.5. Differentially Expressed Proteins in PC3 Prostate Cancer Cells against RWPE-1 Normal Prostate Epithelial Cells without Exogenous Zinc Exposure

PC3 prostate cancer cells showed 30 downregulated (green circle) and 14 upregulated (red circle) protein spots (Figure 3(a)) compared to RWPE-1 prostate normal epithelial cells without zinc exposure (T0). The abundance of tumour suppressor proteins, such as 14-3-3 protein σ (SFN), latexin (LXN), glutathione S-transferase P (GSTP1), Rho GDP-dissociation inhibitor 1 (ARHGDIA), serpin B5 (SERPINB5), and glycine tRNA ligase (GARS1), was reduced in PC3 cells compared to RWPE-1 at T0 (Table 2). Also reduced are the calcium-binding proteins annexin A1 (ANXA1) and annexin A5 (ANXA5), mitochondrial ATP synthase subunit α (ATP5F1A), ATP-dependent RNA helicase DDX39A (DDX39A), RNA helicase (DDX48), dihydrolipoamide S-succinyltransferase (DLST), exosome complex component MTR3 (EXOSC6), T-complex protein 1 subunit α (TCP1), and ubiquitin carboxyl-terminal hydrolase (USP14) (Table 2). The upregulated proteins, such as protein S100A6 (S100A6), aldehyde dehydrogenase 1 family member A3 isoform (ALDH1A3), 26S proteasome non-ATPase regulatory subunit 11 (PSMD11), elongation factor 1 δ (EEF1D), 60 kDa heat shock protein mitochondrial (HSPD1), heat shock protein 90 kDa α (cytosolic) class B member 1 isoform (HSP90AB1), heat shock protein β 1 (HSPB1), L-lactate dehydrogenase B chain (LDHB), peroxiredoxin 6 (PRDX6), proteasome subunit α type 1 (PSMA1), superoxide dismutase (Cu-Zn) (SOD1), and acetyltransferase component of pyruvate dehydrogenase complex (DLAT), are related to cancer cell proliferation, growth, and invasion (Table 2).

Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of PC3 T0 vs RWPE-1 T0 and PC3 T120 vs RWPE-1 T120. (a) Representative 2-DE gel images (in the left panel) of prostate normal RWPE-1 cells without zinc exposure (RWPE-1 T0) and prostate cancer PC3 cells without zinc exposure (PC3 T0). (b) Representative 2-DE gel images (in the right panel) of prostate normal RWPE-1 cells with exogenous zinc exposure for 120 min (RWPE-1 T120) and prostate cancer PC3 cells with exogenous zinc exposure for 120 min (PC3 T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of PC3 T0 vs RWPE-1 T0 and PC3 T120 vs RWPE-1 T120. (a) Representative 2-DE gel images (in the left panel) of prostate normal RWPE-1 cells without zinc exposure (RWPE-1 T0) and prostate cancer PC3 cells without zinc exposure (PC3 T0). (b) Representative 2-DE gel images (in the right panel) of prostate normal RWPE-1 cells with exogenous zinc exposure for 120 min (RWPE-1 T120) and prostate cancer PC3 cells with exogenous zinc exposure for 120 min (PC3 T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Table 2. Identified proteins in prostate cancer cells (PC3) and normal prostate epithelial cells (RWPE-1) with or without exogenous zinc exposure.
Spot ID Identified proteins Gene ID Protein accession Theoretical MW (kDa)/pI Observed MW (kDa)/pI PLGS score Matched peptides Sequence coverage (%) (Fold change/p value) Molecular functions
PC3 T0/RWPE-1 T0 PC3 T120/RWPE-1 T120 PC3 T120/PC3 T0 RWPE-1 T120/RWPE-1 T0
75 14-3-3 protein σ SFN P31947 27.8/4.5 27.3/3.8 932 3 6 (0.4/0.001) ↓ I
76 14-3-3 protein θ YWHAQ P27348 27.8/4.5 27.3/4.7 15878 15 40 (0.4/0.003) ↓ (1.5/0.0009) ↑ II
77 40S ribosomal protein S18 RPS18 P62269 17.7/11.4 17.5/5.7 2004 6 38 (0.5/0.03) ↓ (0.3/0.02) ↓ III, IV
78 Transaldolase TALDO1 A0A140VK56 37.5/6.4 39.1/5.6 423 11 18 (1.7/0.01) ↑ V
79 60S acidic ribosomal protein P0 RPLP1 A0A024RBS2 34.3/5.6 42.3/4.1 208 3 7 (1.4/0.01) ↑ (1.5/0.006) ↑ VI
80 Adenosylhomocysteinase AHCY A0A384MTQ3 47.7/5.9 50.9/5.9 657 20 22 (0.5/0.005) ↓ V
81 Aldehyde dehydrogenase 1 family member A3 isoform CRA a ALDH1A3 A0A024RC95 56.1/7 74.4/7.7 3883 39 30 (1.5/0.02) ↑ V
82 Annexin A1 ANXA1 P04083 38.7/6.6 42.6/6.6 24829 27 55 (0.2/0.02) ↓ (0.3/0.04) ↓ VII
83 Annexin A5 ANXA5 P08758 35.9/4.7 33.4/5.1 12361 20 50 (0.2/0.0008) ↓ (0.3/0.004) ↓ VII
84 26S proteasome non-ATPase regulatory subunit 11 PSMD11 O00231 47.4/6.1 53.9/6.7 1037 18 34 (4.0/0.0009) ↑ (0.3/0.004) ↓ V
85 ATP synthase subunit α mitochondrial ATP5F1A P25705 59.7/9.4 56.3/7.8 26896 25 45 (0.4/0.008) ↓ (0.6/0.04) ↓ III, V
86 Calreticulin CALR P27797 48.1/4.1 81.3/4.4 9707 32 70 (1.7/0.007) ↑ VIII
87 Chaperonin containing TCP1 subunit 6A (ζ 1) isoform CRA a CCT6A A0A024RDL1 58/6.2 78.0/6.2 1700 21 33 (0.7/0.02) ↓ (0.6/0.003) ↓ VIII
88 Clathrin light chain A CLTA P09496 27/4.2 35.4/4.2 1196 8 14 (1.8/0.02) ↑ IV
89 Cytochrome c oxidase subunit 5A mitochondrial COX5A H3BRM5 7.8/5.7 14.2/5.0 1969 4 35 (0.6/0.01) ↓ (0.5/0.03) ↓ VII
90 ATP-dependent RNA helicase DDX39A DDX39A O00148 49.1/5.3 62.9/5.6 3285 8 14 (0.6/0.004) ↓ V
91 RNA helicase DDX48 A0A024R8W0 46.8/6.3 58.3/6.2 4579 49 38 (0.5/0.02) ↓ (2.9/0.006) ↑ V
92 Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) isoform CRA a DLST A0A024R6C9 48.7/9.3 62.9/5.8 2675 12 18 (0.2/0.0003) ↓ (0.6/0.03) ↓ V
93 Dihydropyrimidinase-related protein 2 DPYSL2 A0A1C7CYX9 73.5/5.9 81.9/6.0 3385 19 29 (0.3/0.001) ↓ V
94 Dopamine receptor interacting protein 4 DRIP4 Q4W4Y1 96.0/6.1 158.9/6.1 5782 44 38 (0.3/0.004) ↓ II
95 S-Adenosylmethionine synthase MAT2A B4DEX8 39.7/5.6 52.2/6.1 1183 16 27 (1.3/0.03) ↑ V
96 Elongation factor 1 δ EEF1D A0A087X1X7 69.2/6.8 40.1/5.0 26412 18 23 (1.6/0.03) ↑ (1.4/0.04) ↑ (1.2/0.03) ↑ VI
97 Elongation factor 1 γ EEF1G P26641 50.1/6.2 54.3/6.0 2159 10 18 (0.4/0.004) ↓ VI
98 Elongation factor Tu TUFM A0A384ME17 49.8/7.4 50.5/6.7 2726 51 33 (5.1/0.0004) ↑ VI
99 Ethanolamine-phosphate cytidylyltransferase PCYT2 I3L1R7 41.4/7.0 54.3/7.2 803 9 23 (0.1/0.008) ↓ IX
100 Eukaryotic translation initiation factor 3 subunit E EIF3E B2R806 52.2/5.6 57.9/5.7 1850 11 21 (2.0/0.002) ↑ VI
101 Eukaryotic translation initiation factor 3 subunit I EIF3I Q13347 36.5/5.3 40.1/5.6 1091 6 17 (3.4/0.0003) ↑ VI
102 Exosome complex component MTR3 EXOSC6 Q5RKV6 28.2/6.0 29.5/5.9 795 13 19 (0.3/0.001) ↓ (0.6/0.01) ↓ III
103 F-Actin-capping protein subunit β CAPZB A0A384MR50 30.6/5.6 30.1/5.7 3939 12 27 (0.6/0.006) ↓ X
104 Glucose-6-phosphate 1-dehydrogenase G6PD A0A384NL00 59.2/6.4 71.2/7.1 8928 24 38 (5.5/0.01) ↑ IX
105 Glutamate dehydrogenase GLUD1 B4DMF5 56.6/6.8 65.4/7.5 4823 19 37 (0.6/0.009) ↓ IX
106 Glutathione S-transferase P GSTP1 P09211 23.3/5.3 24.6/5.6 21246 47 67 (0.3/0.006) ↓ (0.4/0.0002) ↓ V
107 Histone H4 HIST1H4J B2R4R0 11.4/11.8 34.9/9.2 3206 8 62 (0.3/0.02) ↓ (1.5/0.03) ↑ IV
108 Glycine tRNA ligase GARS1 A0A090N8G0 77.5/5.8 116.0/5.9 5889 112 41 (0.3/0.00001) ↓ V
109 60 kDa heat shock protein, mitochondrial HSPD1 A0A024R3W0 61.0/5.6 70.7/5.6 16269 32 48 (1.5/0.02) ↑ (1.9/0.0005) ↑ (2.9/0.01) ↑ VIII
110 Heat shock 70 kDa protein 1B HSPA1B A0A0G2JIW1 70.1/5.3 90.2/5.6 10234 35 40 (1.5/0.02) ↑ (0.5/0.004) ↓ VIII
111 Heat shock protein 90 kDa alpha (cytosolic) class B member 1 isoform CRA a HSP90AB1 A0A024RD80 83.2/4.8 123.6/5.3 10935 37 41 (1.8/0.002) ↑ VIII
112 Heat shock protein β 1 HSPB1 P04792 22.8/6.0 27.1/5.4 5134 9 42 (2.1/0.02) ↑ (2.2/0.02) ↑ VIII
113 Aspartate aminotransferase GOT1 A0A140VK69 46.2/6.6 46.4/7.5 682 20 24 (0.40/0.004) ↓ V
114 Histidine tRNA ligase, cytoplasmic HARS1 B4DDD8 48.5/5.0 58.3/5.6 548 5 11 (0.6/0.03) ↓ V
115 Copine 1 CPNE1 B0QZ18 59.7/5.6 90.2/5.6 11670 27 26 (1.8/0.004) ↑ V
116 Latexin LXN Q9BS40 25.7/5.4 29.8/5.6 1946 19 23 (0.8/0.02) ↓ II
117 Leukotriene A (4) hydrolase LTA4H A0A140VK27 69.2/5.7 90.9/5.8 2315 27 24 (0.2/0.01) ↓ VII
118 L-Lactate dehydrogenase B chain LDHB A0A5F9ZHM4 37.4/5.8 34.6/5.6 2746 8 23 (2.0/0.01) ↑ (2.2/0.0003) ↑ (0.7/0.03) ↓ V
119 L-Lactate dehydrogenase LDHA A0A3B3IS95 30.7/6.1 45.0/5.7 3821 14 25 (1.9/0.02) ↑ V
120 MAD1 mitotic arrest deficient-like 1 MAD1L1 A4D218 91.7/8.1 134.2/4.8 738 23 26 (0.5/0.04) ↓ II
121 Moesin MSN P26038 67.8/6.0 102.0/6.1 3846 26 32 (0.7/0.004) ↓ (1.6/0.002) ↑ VIII
122 Myosin light polypeptide 6 MYL6 B7Z6Z4 26.7/4.8 14.1/4.7 5045 6 24 (0.3/0.006) ↓ VII
123 Protein NDRG1 NDRG1 A0A024R9I3 39.5/6.1 53.9/5.6 8387 11 27 (1.8/0.03) ↑ II
124 NSFL1 cofactor p47 NSFL1C Q9UNZ2 40.6/4.8 47.4/5.2 11230 29 65 (5.0/0.0003) ↑ (2.4/0.004) ↑ VIII
125 Peroxiredoxin 6 PRDX6 A0A024R938 25.0/6.0 25.3/6.2 4671 45 52 (8.4/0.0007) ↑ (2.8/0.02) ↑ (0.2/0.03) ↓ V
126 Peroxiredoxin 2 PRDX2 P32119 21.9/5.6 20.9/5.6 4964 13 40 (2.4/0.0003) ↑ V
127 Plastin 3 PLS3 P13797 69.3/5.5 86.1/5.6 1149 12 17 (0.6/0.01) ↓ VII
128 Prohibitin PHB A8K401 29.8/5.4 26.6/5.6 3671 17 55 (2.5/0.0001) ↑ XI
129 Prostaglandin E synthase 3 PTGES3 A0A087WYT3 19.1/4.2 19.8/4.1 339 11 14 (2.1/0.03) ↑ VIII
130 Proteasome (prosome macropain) activator subunit 3 (PA28 γ ki) isoform CRA a PSME3 A0A024R203 30.9/6.3 31.7/5.7 3923 12 36 (1.7/0.04) ↑ I
131 Proteasome subunit α type 1 PSMA1 P25786 29.5/6.2 29.8/6.8 3657 10 35 (9.5/0.0005) ↑ III
132 Protein DDI1 homolog 2 DDI2 Q5TDH0 44.5/4.8 56.3/5.1 320 4 12 (0.2/0.007) ↓ V
133 Protein disulfide-isomerase P4HB A0A024R8S5 57.1/4.6 67.7/4.9 21868 53 66 (1.4/0.03) ↑ V
134 Protein kinase C substrate 80K-H isoform CRA a (glucosidase 2 subunit beta) PRKCSH A0A024R7F1 59.3/4.1 133.2/4.5 2052 10 18 (2.1/0.01) ↑ V, VII
135 Protein S100A6 S100A6 P06703 10.2/5.2 12.1/5.3 3080 6 33 (1.6/0.039) ↑ VII
136 Protein SET SET Q01105 33.5/4.0 50.9/4.4 4249 14 33 (0.2/0.0002) ↓ (0.4/0.0001) ↓ (1.7/0.02) ↑ (0.7/0.004) ↑ VIII, XII
137 Rho GDP-dissociation inhibitor 1 ARHGDIA P52565 23.2/4.8 25.5/5.1 4058 13 43 (0.6/0.006) ↓ V
138 40S ribosomal protein SA RPSA A0A024R2L6 32.8/4.6 52.2/5.0 8860 69 27 (0.5/0.0003) ↓ (1.5/0.006) ↑ IV
139 Serpin B5 SERPINB5 A0A024R2B6 42.1/4.9 42.6/5.7 14963 33 63 (0.3/0.002) ↓ (0.4/0.006) ↓ V
140 Staphylococcal nuclease domain-containing protein SND1 A0A140VK49 101.9/6.8 158.9/7.6 4962 70 48 (0.3/0.00009) ↓ V
141 Stathmin STMN1 P16949 17.3/5.7 18.0/5.4 2472 9 45 (5.1/0.03) ↑ IV
142 Succinate dehydrogenase (ubiquinone) flavoprotein subunit mitochondrial SDHA A0A024QZ30 72.7/7.0 90.9/6.2 2908 15 20 (0.6/0.03) ↓ V
143 Superoxide dismutase (Cu-Zn) SOD1 P00441 15.9/6.7 17.4/5.7 6360 3 18 (2.3/0.004) ↑ VIII
144 T-Complex protein 1 subunit α TCP1 P17987 60.3/5.7 74.4/5.8 4205 14 22 (0.6/0.025) ↓ (0.4/0.05) ↓ (4.6/0.02) ↑ VIII
145 Eukaryotic translation initiation factor 3 subunit F EIF3F B3KSH1 39.1/5.1 54.3/5.1 10070 7 25 (1.4/0.005) ↑ II
146 Torsin-1A-interacting protein 1 TOR1AIP1 A0A0A0MSK5 52.4/6.6 71.2/6.1 1483 14 33 (0.2/0.003) ↓ V
147 Tropomyosin 3 isoform 2 TPM3 A0A0S2Z4G8 28.7/4.5 32.4/4.9 12626 25 63 (1.5/0.002) ↑ X
148 Tubulin α 1A chain TUBA1A Q71U36 50.1/4.8 68.2/5.1 74078 20 49 (0.5/0.002) ↓ (0.6/0.007) ↓ (1.3/0.02) ↑ IV
149 Ubiquitin carboxyl-terminal hydrolase USP14 A6NJA2 51.1/5.6 78.0/5.6 2543 4 8 (0.5/0.03) ↓ (0.5/0.003) ↓ (3.0/0.004) ↑ V
150 Zyxin ZYX Q15942 61.2/6.2 116.0/6.2 768 7 16 (0.6/0.02) ↓ VII
151 Acetyltransferase component of pyruvate dehydrogenase complex DLAT B4DJX1 62.7/5.4 101.2/5.6 1844 24 17 (1.6/0.01) ↑ V
  • Note. MW stands for molecular weight, kDa for kilo Dalton, pI for isoelectric point, PLGS for ProteinLynx Global Server, T0 for 0 min or without zinc exposure (control), T120 for 120 min, ↑ for upregulation, ↓ for downregulation, PC3 for prostate cancer cells, and RWPE-1 for prostate normal epithelial cells. The PLGS score, protein accession, theoretical MW/pI, matched peptides, and sequence coverage (%) were obtained using ProteinLynx Global Server (PLGS) software (version 3.0, Waters Corporation, USA) and the UniProt (Homo sapiens, human) database. Gene ID was derived from UniProt database. The observed MW and pI were calculated according to the protein standards. The fold changes and p values were acquired from the quantitative analysis of the gel images (each group n = 3) by Delta2D software (version 4.0.8, DECODON Gmbh, Germany). PC3 T0/RWPE-1 T0 is the expression fold change of the proteins in PC3 cells compared to RWPE-1 cells without zinc exposure (T0), PC3 T120/RWPE-1 T120 is the expression fold change of the proteins in PC3 cells compared to RWPE-1 cells following the zinc exposure for 120 min (T120), PC3 T120/PC3 T0 is the expression fold change of the proteins in PC3 cells following zinc exposure for T120 compared to T0, and RWPE-1 T120/RWPE-1 T0 is the expression fold change of the proteins in RWPE-1 cells following zinc exposure for T120 compared to T0. Molecular functions: I, apoptosis; II, signalling; III, RNA binding; IV, structural; V, catalytic activity; VI, protein synthesis; VII, metal ion binding; VIII, molecular chaperone; IX, metabolism; X, protein binding; XI, transcription; XII, DNA binding.

Based on molecular functions, the 44 proteins belong to three prominent classes including catalytic enzymes (34%), molecular chaperones (19%), and metal ion binding proteins (13%) (Supplementary Figure 5a). By using PANTHER database, the 44 proteins are classified into different groups including 29% catalytic enzymes and 14% translational proteins (Supplementary Figure 5b). The proteins apparently localise in the cytoplasm (44%), nucleus (23%), and mitochondrion (12%) (Supplementary Figure 5c).

3.6. Differentially Expressed Proteins in PC3 Prostate Cancer Cells Compared to RWPE-1 Normal Prostate Epithelial Cells with Exogenous Zinc Exposure

PC3 prostate cancer cells under zinc exposure for 120 min (T120) showed 15 downregulated (green circle) and 22 upregulated (red circle) protein spots compared to RWPE-1 cells (Figure 3(b)). Calcium binding proteins annexin A1 (ANXA1) and annexin A5 (ANXA5) were suppressed and associated with tumorigenesis (Table 2). The suppressed proteins, including mitochondrial ATP synthase subunit α (ATP5F1A), cytochrome c oxidase subunit 5A mitochondrial (COX5A), ethanolamine-phosphate cytidylyltransferase (PCYT2), F-actin-capping protein subunit beta (CAPZB), glutathione S-transferase P (GSTP1), MAD1 mitotic arrest deficient-like 1 (MAD1L1), serpin B5 (SERPINB5), and ubiquitin carboxyl-terminal hydrolase (USP14), and the overexpressed proteins such as L-lactate dehydrogenase B chain (LDHB), prostaglandin E synthase 3 (PTGES3), and protein kinase C substrate 80K-H isoform (PRKCSH) are related to cell proliferation and apoptosis (Table 2). Tumour suppressor protein NDRG1 (NDRG1) and prohibitin (PHB) were increased in PC3 cells under zinc exposure. The overexpressed proteins, such as 60S acidic ribosomal protein P0 (RPLP1), calreticulin (CALR), elongation factor 1δ (EEF1D), elongation factor Tu (TUFM), eukaryotic translation initiation factor 3 subunit E (EIF3E), and eukaryotic translation initiation factor 3 subunit I (EIF3I), are associated with protein translation (Table 2). Molecular chaperones including 60 kDa heat shock protein mitochondrial (HSPD1), heat shock 70 kDa protein 1B (HSPA1B), and heat shock protein β1 (HSPB1) were overexpressed (Table 2). Antioxidant proteins peroxiredoxin 6 (PRDX6) and peroxiredoxin 2 (PRDX2) were also upregulated (Table 2). The 37 proteins are categorised into three key groups including catalytic enzymes (32%), molecular chaperones (19%), and protein synthesis (12%) based on literature and UniProt database (Supplementary Figure 6a). By using PANTHER database, they are classified into catalytic enzymes (34%), molecular chaperones (16%), and translation proteins (16%) (Supplementary Figure 6b), which is in agreement with the categorisation according to molecular function. The identified proteins localise mainly in the cytoplasm (44%), nucleus (20%), and mitochondrion (11%) (Supplementary Figure 6c).

3.7. Differentially Expressed Proteins in PC3 Prostate Cancer Cells with Exogenous Zinc Exposure Compared to PC3 Cells without Zinc Exposure

PC3 cells demonstrated 2 suppressed and 7 overexpressed protein spots under exogenous zinc exposure for 120 min (T120) compared to PC3 cells without zinc exposure (T0) (Figure 4(a)). Tumour suppressor 14-3-3 protein θ (YWHAQ) and translational proteins such as 60S acidic ribosomal protein P0 (RPLP1), elongation factor 1δ (EEF1D), and 40S ribosomal protein SA (RPSA) were overexpressed (Table 2). Overexpressed tropomyosin 3 isoform 2 (TPM3) is related to cancer progression and metastasis (Table 2). Protein disulfide-isomerase (P4HB) was also upregulated which serves as molecular chaperone. Peroxiredoxin 6 (PRDX6) and 26S proteasome non-ATPase regulatory subunit 11 (PSMD11) were downregulated under zinc exposure in PC3 cells (Table 2). The 9 identified proteins showed two prominent molecular functional groups, catalytic enzymes (30%) and protein synthesis (20%) (Supplementary Figure 7a). PANTHER database analysis revealed 38% translational protein class (Supplementary Figure 7b). The identified proteins localise predominantly in the cytoplasm (50%), nucleus (25%), and endoplasmic reticulum (13%) (Supplementary Figure 7c).

Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of PC3 T120 vs PC3 T0 and RWPE-1 T120 vs RWPE-1 T0. (a) Representative 2-DE gel images (in the left panel) of prostate cancer PC3 cells without zinc exposure (PC3 T0) and with exogenous zinc exposure for 120 min (PC3 T120). (b) Representative 2-DE gel images (in the right panel) of prostate normal RWPE-1 cells without zinc exposure (RWPE-1 T0) and with exogenous zinc exposure for 120 min (RWPE-1 T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.
Details are in the caption following the image
Differentially expressed protein spots in 2-DE gels by comparisons of PC3 T120 vs PC3 T0 and RWPE-1 T120 vs RWPE-1 T0. (a) Representative 2-DE gel images (in the left panel) of prostate cancer PC3 cells without zinc exposure (PC3 T0) and with exogenous zinc exposure for 120 min (PC3 T120). (b) Representative 2-DE gel images (in the right panel) of prostate normal RWPE-1 cells without zinc exposure (RWPE-1 T0) and with exogenous zinc exposure for 120 min (RWPE-1 T120). Each protein extract (100 μg) was resolved based on isoelectric point (pI) and molecular weight (MW). The differentially expressed protein spots are shown with red circles denoting upregulation and green circles denoting downregulation.

3.8. Differentially Expressed Proteins in RWPE-1 Prostate Normal Epithelial Cells with Exogenous Zinc Exposure Compared to RWPE-1 Cells without Zinc Exposure

In RWPE-1 cell, 14 suppressed (green circle) and 10 overexpressed (red circle) protein spots were identified following exogenous zinc exposure for 120 min (T120) compared to RWPE-1 cells without zinc exposure (T0) (Figure 4(b)). The reduced proteins, such as chaperonin containing TCP1 subunit 6A (CCT6A), dihydropyrimidinase-related protein 2 (DPYSL2), dihydrolipoamide S-succinyltransferase (DLST), succinate dehydrogenase (ubiquinone) flavoprotein subunit mitochondrial (SDHA), aspartate aminotransferase (GOT1), and L-lactate dehydrogenase B chain (LDHB), are related to cellular metabolism and proliferation (Table 2). Upregulated proteins, such as glucose-6-phosphate 1-dehydrogenase (G6PD), histone H4 (HIST1H4J), tubulin α1A chain (TUBA1A), L-lactate dehydrogenase (LDHA), stathmin (STMN1), and ubiquitin carboxyl-terminal hydrolase (USP14), are also associated with cell metabolism as well as growth (Table 2). The proteins involved in protein folding such as 60 kDa heat shock protein mitochondrial (HSPD1) and T-complex protein 1 subunit α (TCP1) were overexpressed under zinc exposure (Table 2). Based on molecular functions, the 24 proteins were categorised into catalytic enzymes (34%) and molecular chaperones (23%) (Supplementary Figure 8a). Catalytic enzyme (38%) was the prominent protein class according to PANTHER database analysis (Supplementary Figure 8b). The majority proteins localise in the cytoplasm (48%) and nucleus (22%) (Supplementary Figure 8c).

3.9. Functional Interactions of the Differentially Expressed Proteins in Breast and Prostate Cells

By STRING functional protein-protein network analysis, both known and predicted functional interactions were revealed for the differentially expressed proteins in both cancerous and normal breast and prostate cells under the experimental conditions with and without zinc exposure (Supplementary Figures 9 and 10). Heat shock protein 90 kDa α (cytosolic) class B member 1 isoform (HSP90AB1), actin cytoplasmic 1 (ACTB), and triosephosphate isomerase (TPI1) are prominent in the functional network derived from the comparison of breast cancer cells (MCF-7) and normal breast epithelial cells (MCF10A) without zinc exposure (Supplementary Figure 9a). Triosephosphate isomerase (TPI1) displays its prominence again in the functional network of the differentially expressed proteins in MCF-7 T120 compared to MCF10A T120 under zinc exposure (Supplementary Figure 9b). The metal ion binding proteins such as annexin A1 (ANXA1), annexin A5 (ANXA5), protein S100A2 (S100A2), and protein S100A13 (S100A13) are at the peripheral edge of the protein network of MCF-7 breast cancer cells without zinc exposure (Supplementary Figure 9a) and again in the network of the differentially expressed proteins in MCF-7 with zinc exposure compared to MCF10A T120 (Supplementary Figure 9a).

Prohibitin (PHB) is prominent in the functional network of the differentially expressed proteins in the prostate cancer cells (PC3) with zinc exposure (Supplementary Figure 10b), apart from the heat shock proteins encoded by HSPD1, HSPA1B, and HSPB1. Heat shock protein 90 kDa α (cytosolic) class B member 1 isoform (HSP90AB1), proteasome subunit α type 1 (PSMA1), elongation factor γ (EEF1G), and 40S ribosomal protein SA (RPSA) are predominant in the protein network of the differentially expressed proteins in PC3 cells without zinc exposure (Supplementary Figure 10a).

4. Discussion

Zinc dyshomeostasis is the hallmark of breast and prostate cancer cells. Numerous studies have focused on the zinc homeostasis of breast cancer cells or prostate cancer cells, although the current work is the first to investigate these two kinds of cancer cells together in tandem. Furthermore, we examined the total proteomic profiles of breast cancer cells vs normal breast epithelial cells and prostate cancer cells vs normal prostate epithelial cells in the presence or absence of zinc exposure. The differentially expressed proteins with or without zinc exposure in breast cells (MCF-7, MCF10A) (Table 1) and prostate cells (PC3, RWPE-1) (Table 2) in this study are the key datasets, which enhances the understanding of the zinc homeostasis in both breast and prostate cancer cells.

4.1. The Intrinsic Differences between the Cancer Cells and Their Normal Counterparts (without Zinc Exposure)

First, the analysis without extracellular zinc treatment demonstrates the intrinsic differences between breast cancer cells MCF-7 and the normal breast epithelial cells MCF10A, as well as between prostate cancer cells PC3 and the normal counterpart RWPE-1 cells. The proteomic results demonstrate a key feature of breast and prostate cancer cells, namely, the downregulation of tumour suppressors or antitumour proteins.

The results showed the reduction of tumour suppressor 14-3-3 protein σ and θ in MCF-7 and PC3 cancer cells compared to the normal counterparts (Tables 1 and 2), which is in agreement with the previous findings [36, 37]. The 14-3-3 proteins, including seven isoforms such as σ and θ, are associated with cell cycle, signalling, and apoptosis and are usually downregulated for cancer progression [36, 37]. The tumour suppressor protein S100A2 was decreased in MCF-7 cells (Table 1) as previously reported [38, 39]. However, the expression of S100A2 was unchanged in PC3 cells (Table 2), which is consistent with the previous study [40]. Antitumour proteins such as latexin, glutathione S-transferase P, Rho GDP-dissociation inhibitor 1, and serpin B5 were reduced in their expression in PC3 prostate cancer cells (Table 2), in agreement with the previous studies [4144]. Annexin A1 was found to be downregulated in MCF-7 and PC3 cancer cells (Tables 1 and 2), which is related to breast and prostate cancer development [4548]. Also, for the first time, we observed a downregulated antitumour protein, glycine tRNA ligase [49], in PC3 prostate cancer cells but not in breast cancer cells. The downregulation of glycine tRNA ligase could play a role in prostate cancer development.

The proteomic results demonstrate another feature of breast and prostate cancer cells, that is, the upregulation of proteins related to cancer growth and metastasis. α-Smooth muscle actin (α-SMA) and tumour protein D53 (hD53) were overexpressed in MCF-7 cells (Table 1). α-SMA serves as the marker of epithelial-to-mesenchymal transition (EMT) for cancer metastasis [50, 51] and hD53 promotes breast cancer cell proliferation and their expressions are correlated [51]. High expression of F-actin-capping protein subunit β (CAPZB) in the breast cancer cells (Table 1) is linked with α-SMA in regulating breast cancer cell growth and motility [52, 53]. Overexpression of antioxidants in cancer cells enhances the cancer cell proliferation, hence cancer growth in patients. Peroxiredoxin 6, an antioxidant protein, promotes cancer cell proliferation in an oxidative stress environment [54, 55]. Thus, overexpressed peroxiredoxin 6 in MCF-7 cancer cells (1.8-fold, Table 1) and PC3 cancer cells (8.5-fold, Table 2) indicates its role in breast and prostate cancer development. This finding also suggests that peroxiredoxin 6 (PRDX6) is a potential target for anticancer drug development. Glutathione S-transferase Mu 3 (GSTM3) is another antioxidant overexpressed in MCF-7 breast cancer cells (Table 1), while superoxide dismutase (SOD1) was overexpressed in PC3 prostate cancer cells (Table 2). D-3-Phosphoglycerate dehydrogenase, a metabolic enzyme, is involved in redox homeostasis [56]. Its overexpression in MCF-7 breast cancer cells (Table 1) indicates that this enzyme is associated with breast cancer development.

In addition, the results in Tables 1 and 2 demonstrate the overexpression of the proteins related to cancer cell growth, invasion, and metastasis, including heat shock protein β1 [57, 58], 60 kDa heat shock protein [59], heterogeneous nuclear ribonucleoproteins C1/C2 [60], histone H4 [61], nucleoside diphosphate kinase, protein S100A13 [62], radixin [63], and triosephosphate isomerase [64]. Metabolic proteins including aldehyde dehydrogenase 1 family member A3, L-lactate dehydrogenase B chain, cytochrome b5 type B and elongation factor Tu, and elongation factor 1δ were overexpressed in the breast cancer cells (Table 1) and prostate cancer cells (Table 2). Their overexpression could be related to the cancer cell proliferation. Intriguingly, dihydrolipoamide S-succinyl-transferase (E2 component of 2-oxo-glutarate complex) (DLST), a metabolic enzyme of Krebs cycle [65], was upregulated in MCF-7 breast cancer cells (Table 1), but downregulated in PC3 prostate cancer cells (Table 2). The reason for such inverse expression of this enzyme is yet to be examined.

4.2. The Dynamic Expression of Proteins in Breast and Prostate Cancer Cells in Response to Zinc Exposure

The proteomic datasets were obtained by the comparison between breast cancer cells MCF-7 and the normal breast epithelial cells MCF10A in response to the change of extracellular zinc concentration, as well as the comparison between prostate cancer cells PC3 and the control cells in response to the change of extracellular zinc. The analysis demonstrates that the cancer cells upregulated the proteins which are related to lysosomal activity, antioxidant activity, stress response, cancer growth, cellular structure, and metabolism.

MCF-7 breast cancer cells showed overexpression of cathepsin D in response to zinc exposure (Table 1). Cathepsin D is an aspartic endoproteinase in lysosome and is well known for its roles in angiogenesis, proliferation, and invasion in breast cancer [66, 67]. The change of extracellular zinc should lead to the elevation of cytoplasmic zinc in MCF-7 cells, which might in turn result in higher zinc level in lysosome and hence cathepsin D upregulation. Because zinc enhances cathepsin D activity in lysosome [68], the overexpression of this endoproteinase might be accompanied with increased proteinase activity in zinc-treated MCF-7 cells. Interestingly, peroxiredoxin 6 was overexpressed only in PC3 prostate cancer cells under the zinc exposure, in contrast to its overexpression previously described in both MCF-7 and PC3 cells without zinc exposure. Additionally, peroxiredoxin 2 was also overexpressed in PC3 cells under zinc exposure. The findings demonstrate that peroxiredoxin 6 is related to the cancer development and stress response while peroxiredoxin 2 is likely more relevant to stress response. Antioxidant proteins, including glutathione S-transferase Mu 3 and mitochondrial NADH dehydrogenase (ubiquinone) iron-sulfur protein 3, were overexpressed in breast cancer cells under zinc exposure (Table 1). A previous study showed that glutathione S-transferase Mu 3 expression has a positive relationship with zinc [69]. The molecular chaperones such as mitochondrial 60 kDa heat shock protein, heat shock 70 kDa protein 1B, and heat shock protein β1 were overexpressed in PC3 cancer cells upon zinc exposure (Table 2), which is likely a part of stress response for the prostate cancer cells.

Zinc enhances breast cancer growth. This is evidently supported by the increased intracellular zinc level in breast cancer cells compared to the normal breast epithelial cells [11, 70, 71]. The proteomic dataset showed the elevated expression of tumour protein D53 (hD53 encoded by TPD52L1) and tumour protein D54 (hD54 encoded by TPD52L2) of MCF-7 breast cancer cells in response to the change of extracellular zinc (Table 1), which explains to some extent why zinc promotes breast cancer growth. This finding also suggests that hD53 and hD54 are potential targets for anticancer drug development against breast cancers.

Intriguingly, the change of extracellular zinc resulted in overexpression of prohibitin (PHB) in prostate cancer cells (PC3) (Table 2). Prohibitin can act as a tumour suppressor in prostate cancers [72]. As is known, the intracellular zinc level in prostate cancer cells is lower than the normal counterparts [5, 71]. The variation of extracellular zinc should lead to the increased level of zinc inside the PC3 cancer cells, which is detrimental to the prostate cancer cells. The overexpression of prohibitin might partly explain the cytotoxicity of excess zinc for the prostate cancer cells. Moreover, the reduction of metabolic enzymes including D-3-phosphoglycerate dehydrogenase, adenylosuccinate lyase, inosine-5′-monophosphate dehydrogenase, and translational elongation factor Tu under zinc exposure (Table 1) might be relevant to the decreased cell viability in MCF-7 breast cancer cells under zinc exposure [10], but the expression of these metabolic enzymes is not changed in PC3 prostate cancer cells.

Further proteomic analysis was also done by comparing breast cancer cells MCF-7 with and without zinc treatment, as well as comparing the prostate cancer cells PC3 with and without zinc treatment. Firstly, MCF-7 breast cancer cells exhibited 25 differentially expressed proteins (Table 1) under zinc exposure compared to without zinc exposure (T0), while PC3 prostate cancer cells showed only 9 differentially expressed proteins (Table 2). This very fact demonstrates that breast cancer cells are more capable responders to the variation of extracellular zinc levels. Their molecular network of zinc homeostasis might be more sophisticated than the one in prostate cancer cells.

The findings demonstrate that zinc upregulates the proteins related to breast cancer growth and metastasis. Zinc exposure upregulated actinin α1 and annexin A5 in MCF-7 cells (Table 1). The cytokinetic protein actinin α1 is shown to promote tumorigenesis and epithelial-to-mesenchymal transition (EMT) in cancer via AKT/GSK3β/β catenin signalling pathways [73]. Among 12 annexin A isoforms (annexin A1-11 and annexin A13), annexin A5 in particular has unphosphorylated short N-terminus which enables this protein to exhibit a wide range of functions such as signalling, cancer cell growth, and invasion [74]. The overexpression of both inorganic pyrophosphatase (PPA1) and tubulin α1c (TUBA1C) in response to the variation of exogenous zinc in MCF-7 cells (Table 1) suggests that high intracellular zinc promotes the metabolic activity of breast cancer cells, since inorganic pyrophosphatase is involved in cell metabolism, and tubulin α1c promotes glycolysis in breast cancer [7577]. In addition, current finding demonstrates that heat shock 70 kDa protein was overexpressed in MCF-7 cells (Table 1), correlating well with its overexpression at the gene level [78].

4.3. Interactions of the Differentially Expressed Proteins in Cancer Cells

Human triosephosphate isomerase (TPI1) is a key glycolytic enzyme, and glycolysis is accelerated in cancer cells [79]. The prominence of triosephosphate isomerase in breast cancer cells (MCF-7) with and without zinc exposure (Supplementary Figures 9a and 9b) demonstrates that it is potentially associated with breast cancer development. The marked upregulation of triosephosphate isomerase in MCF-7 cells without zinc exposure (T0) and with zinc exposure (T120) compared to the normal counterparts (Table 1) reflects both its intrinsic expression in the breast cancers and dynamic zinc-responsiveness upon zinc exposure. Triosephosphate isomerase was found to be involved in PI3K/AKT/mTOR signalling pathway and hence breast cancer development [64], which supports the significance of the finding for triosephosphate isomerase in this study. Therefore, it is potentially a druggable target, and it is indeed under investigation for anticancer drug development [80]. The metal-binding proteins, S100A2 and S100A13, belong to S100 protein family, which were first identified by Moore in 1965 [81, 82]. There are 18 members of S100A (S100A1–S100A18). Protein S100A13 is present in the functional networks of MCF-7 with and without zinc exposure (Supplementary Figures 9a and 9b), and it was highly overexpressed both intrinsically in MCF-7 without zinc exposure and responsively to zinc exposure in MCF-7 cells. The findings suggest that S100A13 is involved in zinc homeostasis of breast cancer cells. Prohibitin (PHB) is a worthwhile target for future investigations according to its overexpression in the prostate cancer cells (PC3) at T120 zinc exposure compared to the normal counterparts (Table 2) as well as its prominence in the functional protein network of PC3 T120 vs RWPE-1 T120 (Supplementary Figure 10b). Prohibitin is a pleiotropic chaperone/scaffold tumour suppressor protein implicated in the regulation of cell proliferation and apoptosis [83]. This study, for the first time, demonstrated that it is also a zinc-responsive protein in the prostate cancer cells.

5. Conclusion

The systematic approach of high-resolution top-down proteomics was carried out simultaneously, for the first time, on the cancerous breast and prostate cells (MCF-7, PC3) and the normal breast and prostate cells (MCF10A, RWPE-1). The datasets revealed the intrinsic differences in the proteomes of cancer cells (MCF-7 and PC3) and their normal counterparts without zinc treatment, such as the downregulation of antitumour proteins (14-3-3 protein σ, protein S100A2, latexin, and annexin A1) and the upregulation of tumour protein (hD53), antioxidants (peroxiredoxin 6 and superoxide dismutase), and metabolic enzymes (dihydrolipoamide S-succinyltransferase and aldehyde dehydrogenase 1) in both breast and prostate cancer cells. The zinc-responsive proteomes were then unravelled by their dynamic expressions prodded by the change of extracellular zinc, particularly observed were the increased expressions of tumour proteins (hD53, hD54) and triosephosphate isomerase in breast cancer cells. As the cytoplasmic zinc level is elevated in breast cancer cells, the overexpression of those zinc-responsive proteins could be involved in breast cancer development. Moreover, the upregulation of metal binding protein S100A13 likely plays a role in zinc homeostasis of breast cancer cells. The overexpression of the tumour suppressor prohibitin (PHB) in prostate cancer cells (PC3) in response to the change of extracellular zinc provides an explanation for the inhibitory effect of zinc in prostate cancer development. The upregulation of antioxidants in both kinds of cancer cells under zinc exposure, such as peroxiredoxin 6, would benefit cancer cell growth in response to the change of environmental conditions. Overall, the findings here uncovered significant molecular targets for anticancer drug development and enhanced our knowledge as well as understanding of the role of zinc in breast and prostate cancer cells.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

SKB was responsible for the experimental work, data analysis, and manuscript preparation. MKS and CSM assisted with LC-MS/MS data analysis. DAM, MJW, and CSM supervised the study and revised the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

The experimental works have been done by Dr. Shital Barman in the past four years with the support of Western Sydney University. Open-access publishing was facilitated by Western Sydney University, as part of the Wiley-Western Sydney University agreement via the Council of Australian University Librarians. The authors acknowledge Western Sydney University Mass Spectrometry Facility in School of Medicine.

    Data Availability

    All data are included in the article and the supplementary file.

      The full text of this article hosted at iucr.org is unavailable due to technical difficulties.